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Increased Levels of the Soluble Variant of the Vascular
Endothelial Growth Factor Receptor VEGFR-1 Are Associated
with a Poor Prognosis in Wound Healing
To the Editor:
During cutaneous wound healing, the development of gran-
ulation tissue requires the formation of new capillaries, and
the absence of this tissue is a typical feature of chronic non-
healing wounds (Luetolf et al, 1993; Bollinger et al, 1997).
Local mechanisms leading to impaired angiogenesis in
chronic non-healing wounds are poorly understood. Vas-
cular endothelial growth factor (VEGF)-A is a pivotal mol-
ecule in driving the angiogenic response in wound repair
(Brown et al, 1992; Frank et al, 1995; Nissen et al, 1998;
Kishimoto et al, 2000; Kuo et al, 2001). So far, soluble
vascular endothelial growth factor receptor-1 (sVEGFR-1), a
splice variant of the membrane-bound VEGFR-1, is con-
sidered the only naturally occurring specific inibitor for
VEGF-A. In vitro analysis demonstrated that sVEGFR-1 is a
strong and specific inhibitor of VEGF-A-mediated actions
and in vivo studies proved that the recombinant secreted
form of the extracellular region of VEGFR-1 is a potent in-
hibitor of angiogenesis (Kendall and Thomas, 1993; Aiello
et al, 1995; Miotla et al, 2000; Mori et al, 2000). Potentially,
sVEGFR-1 functions as an inert decoy receptor by binding
VEGF-A and thereby regulating the availability of VEGF-
related ligands for activation of VEGFR-2 (Flk-1/KDR), the
VEGF receptor principally involved in VEGF signalling
(Kendall and Thomas, 1993; Barleon et al, 1997; Hiratsuka
et al, 1998). Beside VEGF-A, VEGFR-1 binds the VEGF-
related proteins placenta growth factor (PIGF) and VEGF-B,
but with much lower affinity (Kendall and Thomas, 1993;
Hornig et al, 2000; Shibuya 2001). Although the precise
function of PIGF and VEGF-B during cutaneous wound
repair is presently unknown, recent data indicate that
membrane-bound VEGFR-1 might be a critical signalling
receptor for PIGF during cutaneous tissue repair (Failla et al,
2000; Carmeliet et al, 2001). Expression of sVEGFR-1 has
been described in a variety of primary human endothelial
cells, in various cancer tissues and different biological fluids
(Kendall and Thomas, 1993; Barleon et al, 1997; Banks et al,
1998; Hornig et al, 1999; Hornig et al, 2000; Vuobela et al,
2000; Barleon et al, 2001; Tor et al, 2002). The significance
of naturally occurring sVEGFR-1 is unclear at this time. In
this study we investigated the hypothesis whether sVEGFR-
1 plays a role during cutaneous wound repair and we eval-
uated the expression of sVEGFR-1 in normal healing and
chronic non-healing cutaneous wounds. To assess
sVEGFR-1 secretion, sVEGFR-1 protein was quantified by
ELISA in wound fluid obtained from patients of normal
healing cutaneous acute wounds after patients provided
written, informed consent (patients n¼ 11, excision wounds
of the lower leg awaiting wound closure by secondary in-
tention, postoperative days 3 or 4, mean age of patients
65  16 y) and non-healing chronic wounds of patients pre-
senting with chronic venous insufficiency (patients n¼ 16,
duration of ulcer46 months, mean size 84  49 cm2, mean
age of patients 71  11 y, ulcers showed no clinical sign of
infection and poor granulation tissue formation). In wound
fluid of normal healing wounds sVEGFR-1 levels averaged
at 2.2  2.0 ng per mL. In contrast, mean sVEGFR-1 con-
centration in wound fluid obtained from chronic non-healing
wounds was 9.34  3.2 ng per mL (po0.0001) (Fig 1A).
sVEGFR-1 levels in serum from patients with healing and
non-healing wounds were below 1 ng per mL, indicating
that sVEGFR-1 protein was synthesized and secreted lo-
cally at the wound site. Additionally, the presence of
sVEGFR-1 in wound fluid was verified by western blot anal-
ysis (Fig 1B). The sVEGFR-1 protein present in wound fluid
had a molecular weight of approximately 110 kd, compa-
rable to native sVEGFR-1 isolated from HUVEC or placenta
cell-conditioned media (Fig 1B) (Kendall and Thomas, 1993;
Hornig et al, 1999). Further, expression of sVEGFR-1 and
VEGFR-1 in chronic wound tissue was demonstrated by
RT-PCR analysis and Southern blot analysis of the RT-PCR
products (Fig 1C). Additionally, the specificity of the RT-PCR
products was verified by DNA sequencing.
To assess the heterogeneity of sVEGFR-1 concentra-
tions, particular in chronic wound fluid samples, we inves-
tigated the kinetics of sVEGFR-1 release at different stages
during the healing process. Progression in wound healing
was evaluated by assessing granulation tissue formation
and re-epithelialization by wound tracings at indicated time
points. sVEGFR-1 levels quantified in wound fluid collected
from normal healing wounds were low at initial postopera-
tive days, similar to serum levels, increased during granu-
lation tissue formation up to a maximum and decreased
with wound closure (Fig 2A). During a 2-mo follow-up in our
clinic some of the chronic wounds transformed from a non-
healing in a healing state, characterized by granulation tis-
sue formation and finally wound closure. In these patients
induction of granulation tissue formation and wound closure
was associated with a decrease in sVEGFR-1 concentra-
tions (Fig 2B, wounds #4–6); the positive correlation be-
tween healing progression and sVEGFR-1 decline was
statistically significant (r¼ 0.92, po0.0005). In contrast,
Abbreviations: VEGF, vascular endothelial growth factor; VEGFR,
VEGF receptor; sVEGFR, soluble VEGFR
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sVEGFR-1 levels in chronic wounds which did not develop
granulation tissue and did not diminish in wound size over a
period of 2 mo remained high (Fig 2B, wounds #7–9). For all
wounds therapy followed the principals of moist wound
therapy combined with compression therapy in venous ul-
cers. Interestingly, the kinetics of sVEGFR-1 secretion in
normal healing wounds resembles those described for
VEGF-A/PIGF expression during normal wound repair, indi-
cating a temporal correlation of sVEGFR-1 and VEGF ligand
expression during wound angiogenesis (Nissen et al, 1998;
Failla et al, 2000; Carmeliet et al, 2001). This observation
supports the idea that during physiological angiogenesis
sVEGFR-1 may control a local overshooting response of the
increasing VEGF-related ligands. In contrast, induction of
sVEGFR-1 expression to non-physiological levels, as
measured in chronic non-healing wounds, indicate a dis-
turbance of the VEGF ligand/sVEGFR-1 balance; potentially,
this dysregulation may attenuate vessel growth during
granulation tissue formation and hence impair wound
closure.
To investigate whether wound fluid contains mediators
capable of inducing VEGFR-1 and sVEGFR-1 mRNA ex-
pression, we analyzed VEGFR-1 and sVEGFR-1 mRNA ex-
pression in HUVE cells following exposure to wound fluid.
Densitometric analysis of the corresponding Northern blot
analysis demonstrated that wound fluid obtained from
chronic non-healing wounds was significantly stronger
in inducing sVEGFR-1 mRNA expression in comparision
to wound fluid obtained from healing wounds (data
not shown). This data suggests that inducing sVEGFR-1
expression to non-physiological levels could not only be
regarded as a cause, but also as a consequence of chronic
ulceration and opens new prospective in understand-
ing which factor in wound fluid is responsible for such an
induction.
In summary, our report reveales the expression of
sVEGFR-1 during cutaneous wound healing suggesting a
function of sVEGFR-1 during tissue repair. Whether in-
creased sVEGFR-1 levels in non-healing wounds interfere
with the activities of VEGF-related ligands and potentially
reduce angiogenesis remains to be investigated in further
studies. Our results, however, lead to the intriguing hypoth-
esis as to whether the sVEGFR-1 level detected in wound
fluid can be of prognostic value for differentiating an effective
or impaired wound healing response. An indicator for healing
would be of great value to assess disease severity and pro-
gression of the chronic wound, and might serve as predictive
indicator for the efficacy of a certain therapy regime.
Figure1
sVEGFR-1 concentration is increased in wound fluid obtained from
non-healing versus normal healing wounds. (A) ELISA analysis:
wound fluid was obtained from patients with normal healing cutaneous
wounds and from patients presenting with chronic venous leg ulcers;
for fluid collection wounds were covered with a semipermeable poly-
urethane film max. 4 h (Hyalofilm, Hartmann; Heidenheim, Germany);
fluids were centrifuged (10 min, 13,000  g, 41C) and frozen (801C)
until use; ELISA for quantification of sVEGFR-1 was described before
(Hornig et al, 1999); samples were analyzed in duplicate at different
dilutions; sVEGFR-1 levels were normalized to mean albumin concen-
trations (healing wound fluid 23.2  1.4 g per L, non-healing wound
fluid 19.1  3.7 g per L); po0.0001 analyzed using the unpaired t test;
(B) western-blot analysis: human serum (lane 1), wound fluid obtained
from non-healing (lane 2) and normal healing (lane 3) wounds, recom-
binant human sVEGFR-1D1–6 (100 ng) (produced in insect cells and
purified as previously described in Roeckl et al, 1998) (lane 4), sVEGFR-
1 isolated from HUVEC-conditioned medium (lane 5); (C) RT-PCR anal-
ysis: total RNA was extracted from normal skin (lanes 1–5) and non-
healing wounds (lanes 6–10); primers were chosen such that trans-
membrane VEGFR-1 and sVEGFR-1 amplification products were 530
and 790 bp, respectively; primers were specific for either VEGFR-1
(EMBL, Accession No.: X51602) (50-CTC ACT GCC ACT CTA ATT GTC
A-30, 50-CAA GTG ATC TGA GGC TCG GGG AC-30), sVEGFR-1 (start
primer is the same as for VEGFR-1, 50-GAG CCT GAA AGT TAG CAA
CAG-30), or S26 (EMBL, Accession No.: U017) (50-GGT CCG TGC CTC
CAA GAT GAC-30, 50-GTC CTT GCG GGC TTC ACG AG-30) (MWG-
Biotech, Ebersberg, Germany); hybridization with a DIG-labeled VEG-
FR-1/sVEGFR-1 gene sequence revealed the expression of the trans-
membrane and the soluble VEGFR-1 in both tissues; RT-PCR of S26
served as standard (ethidium bromide agarose gel electrophoresis).
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ing cutaneous wounds at indicated post operative
days; note different wound sizes at day 0: wound #1:
24 cm2, wound #2: 75 cm2, wound #3: 30 cm2; sam-
ples were assayed in duplicates and results are
shown  SD; (B) wound fluid collected from individu-
al patients presenting chronic non-healing wounds and
when wounds entered (wounds #4–6) or did not enter
(wounds #7–9) a phase of granulation tissue formation
and wound closure; wound size in the non-healing
phase (¼ time point 0): wound #4: 156 cm2, wound #5:
25 cm2, wound #6: 143 cm2, wounds #7–9: 62  20
cm2; samples were assayed in duplicates and results
are shown  SD; wound size during the healing phase
is presented as a percentage of the wound size at time
point 0; arrows indicate the formation of granulation
tissue; sVEGFR-1 was quantified as described above.
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